RecruitingNCT07029542
Home Reported Outcomes in C3G Study
Studying C3 glomerulopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Novartis PharmaceuticalsNovartis Pharmaceuticals
- Enrollment
- 100 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Novartis Investigative Site, East Hanover, New Jersey, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07029542 on ClinicalTrials.govOther trials for C3 glomerulopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07522099Chinese Adults With Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGNCT07156149Fabhalta Capsules Specified Drug-use SurveyNovartis Pharmaceuticals
- RECRUITINGPHASE1NCT07483827A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathyeleva GmbH
- RECRUITINGPHASE3NCT04817618Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.Novartis Pharmaceuticals